JP2023505271A5 - - Google Patents

Info

Publication number
JP2023505271A5
JP2023505271A5 JP2022533615A JP2022533615A JP2023505271A5 JP 2023505271 A5 JP2023505271 A5 JP 2023505271A5 JP 2022533615 A JP2022533615 A JP 2022533615A JP 2022533615 A JP2022533615 A JP 2022533615A JP 2023505271 A5 JP2023505271 A5 JP 2023505271A5
Authority
JP
Japan
Prior art keywords
retromercore
composition
protein
vps26b
vps26a
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2022533615A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023505271A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/063627 external-priority patent/WO2021113824A1/en
Publication of JP2023505271A publication Critical patent/JP2023505271A/ja
Publication of JP2023505271A5 publication Critical patent/JP2023505271A5/ja
Priority to JP2025125690A priority Critical patent/JP2025149978A/ja
Withdrawn legal-status Critical Current

Links

JP2022533615A 2019-12-05 2020-12-07 アルツハイマー病および他の神経変性障害の処置のためのレトロマーの安定化 Withdrawn JP2023505271A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025125690A JP2025149978A (ja) 2019-12-05 2025-07-28 アルツハイマー病および他の神経変性障害の処置のためのレトロマーの安定化

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962943999P 2019-12-05 2019-12-05
US62/943,999 2019-12-05
US202063074578P 2020-09-04 2020-09-04
US63/074,578 2020-09-04
PCT/US2020/063627 WO2021113824A1 (en) 2019-12-05 2020-12-07 Stabilization of retromer for the treatment of alzheimer's disease and other neurodegenerative disorders

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025125690A Division JP2025149978A (ja) 2019-12-05 2025-07-28 アルツハイマー病および他の神経変性障害の処置のためのレトロマーの安定化

Publications (2)

Publication Number Publication Date
JP2023505271A JP2023505271A (ja) 2023-02-08
JP2023505271A5 true JP2023505271A5 (https=) 2023-12-14

Family

ID=76222705

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022533615A Withdrawn JP2023505271A (ja) 2019-12-05 2020-12-07 アルツハイマー病および他の神経変性障害の処置のためのレトロマーの安定化
JP2025125690A Pending JP2025149978A (ja) 2019-12-05 2025-07-28 アルツハイマー病および他の神経変性障害の処置のためのレトロマーの安定化

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025125690A Pending JP2025149978A (ja) 2019-12-05 2025-07-28 アルツハイマー病および他の神経変性障害の処置のためのレトロマーの安定化

Country Status (12)

Country Link
US (1) US20230021959A1 (https=)
EP (1) EP4069315A4 (https=)
JP (2) JP2023505271A (https=)
KR (1) KR20220152192A (https=)
CN (2) CN115297891A (https=)
AU (1) AU2020395327A1 (https=)
BR (1) BR112022011073A2 (https=)
CA (1) CA3160785A1 (https=)
IL (1) IL293599A (https=)
MX (1) MX2022006895A (https=)
PH (1) PH12022551373A1 (https=)
WO (1) WO2021113824A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023159238A1 (en) * 2022-02-21 2023-08-24 The Scripps Research Institute Mef2 transcriptional activators to treat neurologic conditions

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1938104A2 (en) * 2005-10-17 2008-07-02 Institute for Systems Biology Tissue-and serum-derived glycoproteins and methods of their use
US20080214482A1 (en) * 2005-11-15 2008-09-04 Scott Small Retromer-based assays and methods for treating alzheimer's disease
WO2009108274A2 (en) * 2008-02-26 2009-09-03 The University Of North Carolina At Chapel Hill Methods and compositions for adeno-associated virus (aav) with hi loop mutations
EP2607900A1 (de) * 2011-12-22 2013-06-26 Protagen AG Markersequenzen für Brustkrebs und deren Verwendung
MX367100B (es) * 2012-02-17 2019-08-05 The Children´S Hospital Of Philadelphia Composiciones del vector aav y metodos para su transferencia genetica a celulas, organos y tejidos.
WO2014110481A2 (en) * 2013-01-11 2014-07-17 The Trustees Of Columbia University In The City Of New York Rab7l1 interacts with lrrk2 to modify intraneuronal protein sorting and parkinson' s disease risk
US20160250182A1 (en) * 2013-01-11 2016-09-01 The Trustees Of Columbia University In The City Of Rab7l1 interacts with lrrk2 to modify intraneuronal protein sorting and parkinson's disease risk
GB201409519D0 (en) * 2014-05-29 2014-07-16 Univ Leicester Senescent cell biomarkers
AU2016324317A1 (en) * 2015-09-17 2018-03-08 Coda Biotherapeutics, Inc. Compositions and methods for treating neurological disorders
WO2017191274A2 (en) * 2016-05-04 2017-11-09 Curevac Ag Rna encoding a therapeutic protein
WO2018112446A2 (en) * 2016-12-18 2018-06-21 Selonterra, Inc. Use of apoe4 motif-mediated genes for diagnosis and treatment of alzheimer's disease
BR112020006661A2 (pt) * 2017-10-03 2020-10-13 Prevail Therapeutics, Inc. terapias de genes para distúrbios lipossomais
US20190345516A1 (en) * 2018-03-12 2019-11-14 Musc Foundation For Research Development Methods for treating eye disease

Similar Documents

Publication Publication Date Title
JP2023503455A5 (https=)
JP2022531809A5 (https=)
JP2023534999A5 (https=)
JP2022068181A5 (https=)
JP2021512649A5 (https=)
JP2020533959A5 (https=)
JP2022500066A5 (https=)
JP2009526067A5 (https=)
JP2016503405A5 (https=)
JP2021512072A5 (https=)
JP2023534037A5 (https=)
JP2023502515A5 (https=)
JP2017529395A5 (https=)
JP2021525245A5 (https=)
JP2020516244A5 (https=)
JP2022541070A5 (https=)
JP2023537980A5 (https=)
JP2018533976A5 (https=)
JP2022512579A5 (https=)
JP2023505271A5 (https=)
JP2023524414A5 (https=)
JP2022533448A5 (https=)
JP2024527313A5 (https=)
JP2024119900A5 (https=)
JP2024518665A5 (https=)